The Zayed Centre for Research into Rare Disease in Children at Great Ormond Street Hospital (GOSH) in London has already been at the cutting edge of new technologies since it opened in 2019
Aofie Regan, Director of Charitable Programmes and Impact at GOSH's Children's Charity, describes the research that happens there, which is transparently on display for the public to see from the street. In addition to do work directly there that might not be driven forward on its own, they also recently initiated a clinical trials funding programme.
15 hours ago
BIO 2026: Sofinnova Investments' Managing Partner Jim Healy shares his (optimistic) take on the current state of biotech and the venture side of it
He says he sees generalist investors coming back to biotech for the first time in a while, which have been benefitting the IPO market and other areas of the sector. Plus, the areas he is focused on today and what it take to be a successful IPO candidate. Coverage brought to you by
Jun 22
EHA 2026: H.C. Wainwright Senior Biotech Analyst Mitchell Kapoor previews key EHA data from Legend and Incyte, and shares catalysts he is watching for after the conference
He discusses in vivo CAR-T data from Legend, and how Incyte is planning for the loss of exclusivity on Jakafi. Plus, his take on last week's summit data, and watching out for future catalysts from Ionis and Tyra.
Jun 11
At Nucleate UK's The Forum in London, former Novo Nordisk CSO Marcus Schindler reflects on the success of the GLPs and shares advice for biotech entrepreneurs in Europe
He believes that GLPs will always be the backbone of weight loss therapies and points out that they are the only weight loss medicines that have shown a cardiovascular benefit. Plus, why he thinks entrepreneurs in Europe should take a nod from other areas and be more nimble and take more risks in the future.
Jun 7
At Nucleate UK's The Forum, early stage biotech investor Nirmesh Patel of Amino Collective says there is currently a bifurcation in fundraising between biotech co's with an AI angle and those without
He says the mood overall in biotech is dramatically better than it has been during the previous 2-3 years, and he is unsure about whether the AI factor will continue to attract investors like generalists who have been revisiting the sector.
Jun 4
At Nucleate UK's The Forum 2026, Oxford Nanopore Founder Gordon Sanghera shares his take on the next generation of biotech leaders and the innovation ecosystem in the UK
He describes how new technologies will revolutionize biotech, and his hope that more UK companies grow for the long-term rather than being sold to foreign multi-nationals.
Jun 4
.png){kind=logo}